Latest Tau protein Stories
Researchers from Boston University School of Medicine (BUSM) have identified a novel group of proteins that accumulate in the brains of patients with Alzheimer's disease.
5.4 million Americans suffer from Alzheimers and 3 million from Parkinson's disease. Doctors who treat patients with these among other neurodegenerative conditions believe that the diseases are spreading though their patients' brains. The stages of both Alzheimers and Parkinson's disease show these pathological effects.
Researchers at Mount Sinai School of Medicine have gained insight into the mechanism by which a pathological brain protein called tau contributes to the progression of Alzheimer’s disease (AD)
According to a new study, the neuron-killing pathology of Alzheimer's disease (AD), which begins before clinical symptoms appear, requires the presence of both amyloid-beta (a-beta) plaque deposits and elevated levels of an altered protein called p-tau.
Under normal circumstances, the tau protein is a hard-working participant in memory and normal brain functioning.
Repeated stress triggers the production and accumulation of insoluble tau protein aggregates inside the brain cells of mice.
New research in humans published today reveals that the so-called FKBP52 protein may prevent the Tau protein from turning pathogenic.
A new study shows that a new drug, called epothilone D (EpoD) is preventing neurological damage and improving cognitive performance in a mouse model of Alzheimer's disease (AD).
A study published this week in the Journal of Neuroscience shows that the compound epothilone D (EpoD) is effective in preventing further neurological damage and improving cognitive performance in a mouse model of Alzheimer's disease (AD).
A compound that previously progressed to Phase II clinical trials for cancer treatment slows neurological damage and improves brain function in an animal model of Alzheimer's disease.